Potent and Sustained Lowering of Serum Uric Acid by YJH ‐012‐D, a G al NA c‐Conjugated si RNA Targeting Xanthine Dehydrogenase
Pharmacology Research & Perspectives · 2026-08 · 14 (4)
DOI: 10.1002/prp2.70308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 31.07.2026. Verfasst von Tingke Tang und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, Xanthine Dehydrogenase, Uric Acid, Acetylgalactosamine. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hyperuricemia (HUA) is primarily driven by hepatic overproduction of urate, mediated by xanthine dehydrogenase (XDH). This preclinical study evaluates YJH‐012‐D, a N ‐acetylgalactosamine (GalNAc)‐conjugated small interfering RNA (siRNA) targeting hepatic XDH . Functional assays demonstrated that YJH‐012‐D potently suppressed both XDH mRNA and protein expression in primary hepatocytes. In mice, a single subcutaneous dose of 8 mg/kg significantly reduced serum uric acid levels and suppressed hepatic XDH expression for more than 42 days. In cynomolgus monkeys, administration of YJH‐012‐D at 10 mg/kg lowered serum uric acid for up to 180 days, with sustained XDH inhibition observed for 120 days. Pharmacokinetic analysis revealed a high liver‐to‐plasma area under the curve (AUC) ratio (2000–6100) and a hepatic half‐life exceeding 10 days, consistent with prolonged pharmacological activity. Comprehensive toxicity assessments—including clinical biochemistry, histopathology, and RNA sequencing (RNA‐seq)‐based off‐target profiling—identified no significant adverse effects. Collectively, YJH‐012‐D exhibits potent, durable urate‐lowering efficacy and a favorable safety profile, underscoring its potential as a novel therapeutic candidate for HUA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
- Youjia (Hangzhou) Biomedical Technology Co. Ltd, Hangzhou, Zhejiang, China.
- Livzon Pharmaceutical Group Inc, Zhuhai, Guangdong, China.
- Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China.
- General Practice Department, Tianjin First Central Hospital, Tianjin, China.
ORCID-Profile: Qiuying Li, Chenguang Zhang, Chengjiang Zhao
Zitieren
APA
Tang, T., Li, Q., Zhang, C., Wang, Y., Yang, L., Huang, H., He, Y., Zheng, Z., Liang, D., Wang, M., Wu, Y., Zhao, C., & Cui, W. (2026). Potent and Sustained Lowering of Serum Uric Acid by YJH ‐012‐D, a G al NA c‐Conjugated si RNA Targeting Xanthine Dehydrogenase. Pharmacology Research & Perspectives, 14(4). https://doi.org/10.1002/prp2.70308
Vancouver
Tang T, Li Q, Zhang C, Wang Y, Yang L, Huang H, et al. Potent and Sustained Lowering of Serum Uric Acid by YJH ‐012‐D, a G al NA c‐Conjugated si RNA Targeting Xanthine Dehydrogenase. Pharmacology Research & Perspectives. 2026;14(4). doi:10.1002/prp2.70308
BibTeX
@article{Tang2026,
author = {Tang, Tingke and Li, Qiuying and Zhang, Chenguang and Wang, Yongxing and Yang, Lu and Huang, Haibin and He, Yujun and Zheng, Zhi and Liang, Dong and Wang, Meng and Wu, Yingyu and Zhao, Chengjiang and Cui, Wenhao},
title = {Potent and Sustained Lowering of Serum Uric Acid by YJH ‐012‐D, a G al NA c‐Conjugated si RNA Targeting Xanthine Dehydrogenase},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {4},
doi = {10.1002/prp2.70308}
}
EUVIMED